Hostname: page-component-848d4c4894-ndmmz Total loading time: 0 Render date: 2024-06-10T23:52:48.489Z Has data issue: false hasContentIssue false

From the Editor-in-Chief

Published online by Cambridge University Press:  03 May 2005

Rights & Permissions [Opens in a new window]

Abstract

Type
From the Editor-in-Chief
Copyright
© 2005 Cambridge University Press

The initial part of this issue is devoted to considerations of infection by the respiratory syncytial virus, an issue which has been the subject of hotly contested correspondence1, 2 following our publication of the recommendations for prophylaxis against the virus made following a meeting of the British Paediatric Cardiac Association,3 now the British Congenital Cardiac Association. In addition to the manuscripts that resulted from the symposium held at the meeting of the European Association for Paediatric Cardiology held in Munich in May of 2004, we are also pleased to publish an original article submitted over the same period from the Royal Liverpool Children's Hospital. We are grateful, however, to Tim Feltes and his colleagues for assembling the material that forms the basis of the papers resulting from the meeting in Munich, and we are the more pleased that Tim himself, as guest editor, has agreed to introduce this important topic in the pages of the Journal.

References

Onuzo O. Re: Recommendation for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young 2004; 14: 469.Google Scholar
Keeton B. Re: Recommendation for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young 2004; 14: 469.Google Scholar
Tulloh R, Marsh M, Blackburn M, et al. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young 2003; 13: 420423.Google Scholar